Show simple item record

dc.contributor.authorIbraheim, Raed
dc.contributor.authorTai, Phillip W L
dc.contributor.authorMir, Aamir
dc.contributor.authorJaveed, Nida
dc.contributor.authorWang, Jiaming
dc.contributor.authorRodríguez, Tomás C
dc.contributor.authorNamkung, Suk
dc.contributor.authorNelson, Samantha
dc.contributor.authorKhokhar, Eraj Shafiq
dc.contributor.authorMintzer, Esther
dc.contributor.authorMaitland, Stacy
dc.contributor.authorChen, Zexiang
dc.contributor.authorCao, Yueying
dc.contributor.authorTsagkaraki, Emmanouela
dc.contributor.authorWolfe, Scot A
dc.contributor.authorWang, Dan
dc.contributor.authorPai, Athma A
dc.contributor.authorXue, Wen
dc.contributor.authorGao, Guangping
dc.contributor.authorSontheimer, Erik J
dc.date.accessioned2023-03-24T13:22:41Z
dc.date.available2023-03-24T13:22:41Z
dc.date.issued2021-11-01
dc.identifier.citationIbraheim R, Tai PWL, Mir A, Javeed N, Wang J, Rodríguez TC, Namkung S, Nelson S, Khokhar ES, Mintzer E, Maitland S, Chen Z, Cao Y, Tsagkaraki E, Wolfe SA, Wang D, Pai AA, Xue W, Gao G, Sontheimer EJ. Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat Commun. 2021 Nov 1;12(1):6267. doi: 10.1038/s41467-021-26518-y. PMID: 34725353; PMCID: PMC8560862.en_US
dc.identifier.eissn2041-1723
dc.identifier.doi10.1038/s41467-021-26518-yen_US
dc.identifier.pmid34725353
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51879
dc.description.abstractAdeno-associated virus (AAV) vectors are important delivery platforms for therapeutic genome editing but are severely constrained by cargo limits. Simultaneous delivery of multiple vectors can limit dose and efficacy and increase safety risks. Here, we describe single-vector, ~4.8-kb AAV platforms that express Nme2Cas9 and either two sgRNAs for segmental deletions, or a single sgRNA with a homology-directed repair (HDR) template. We also use anti-CRISPR proteins to enable production of vectors that self-inactivate via Nme2Cas9 cleavage. We further introduce a nanopore-based sequencing platform that is designed to profile rAAV genomes and serves as a quality control measure for vector homogeneity. We demonstrate that these platforms can effectively treat two disease models [type I hereditary tyrosinemia (HT-I) and mucopolysaccharidosis type I (MPS-I)] in mice by HDR-based correction of the disease allele. These results will enable the engineering of single-vector AAVs that can achieve diverse therapeutic genome editing outcomes.en_US
dc.language.isoenen_US
dc.relation.ispartofNature Communicationsen_US
dc.relation.urlhttps://doi.org/10.1038/s41467-021-26518-yen_US
dc.rightsOpen Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/. © The Author(s) 2021; Attribution 4.0 Internationalen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCRISPR-Cas9 genome editingen_US
dc.subjectTargeted gene repairen_US
dc.titleSelf-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivoen_US
dc.typeJournal Articleen_US
dc.source.journaltitleNature communications
dc.source.volume12
dc.source.issue1
dc.source.beginpage6267
dc.source.endpage
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland
dc.identifier.journalNature communications
refterms.dateFOA2023-03-24T13:22:42Z
dc.contributor.departmentHorae Gene Therapy Centeren_US
dc.contributor.departmentLi Weibo Institute for Rare Diseases Researchen_US
dc.contributor.departmentMolecular, Cell and Cancer Biologyen_US
dc.contributor.departmentMorningside Graduate School of Biomedical Sciencesen_US
dc.contributor.departmentProgram in Molecular Medicineen_US
dc.contributor.departmentRNA Therapeutics Instituteen_US


Files in this item

Thumbnail
Name:
s41467-021-26518-y.pdf
Size:
6.159Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/. © The Author(s) 2021; Attribution 4.0 International
Except where otherwise noted, this item's license is described as Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/. © The Author(s) 2021; Attribution 4.0 International